- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07725393
Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis (POME-PERIO)
Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis: A Randomized Split-Mouth Trial
This randomized, triple-blind, placebo-controlled split-mouth clinical trial aims to evaluate the clinical and biochemical efficacy of subgingival pomegranate peel extract gel as an adjunct to scaling and root planing (SRP) in the treatment of Stage II-III periodontitis.
Thirty-two participants diagnosed with Stage II-III periodontitis will receive SRP in all selected periodontal sites. Test sites will receive locally delivered pomegranate peel extract gel, while contralateral control sites will receive a placebo gel. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), bleeding on probing (BOP), and gingival crevicular fluid levels of matrix metalloproteinase-8 (MMP-8), will be assessed at baseline, 1 month, 3 months, and 6 months to evaluate whether adjunctive pomegranate peel extract gel improves periodontal healing compared with SRP alone.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Gehad Samy, BDS, MSc, PhD
- Telefonnummer: +201092710515
- E-Mail: gehadasaad.26@azhar.edu.eg
Studienorte
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Ägypten
- Rekrutierung
- Faculty of Dental Medicine for Girls, Al-Azhar University
-
Kontakt:
- Gehad Samy, BDS, MSc, PhD
- Telefonnummer: +201092710515
- E-Mail: gehadasaad.26@azhar.edu.eg
-
Hauptermittler:
- Gehad Samy, BDS, MSc, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Adults aged 30 to 60 years.
- Systemically healthy individuals.
- Diagnosis of Stage II or Stage III periodontitis according to the 2018 Classification of Periodontal and Peri-Implant Diseases and Conditions.
- Presence of at least 20 natural teeth.
- Presence of at least two non-adjacent periodontal pockets (≥5 mm) located in different quadrants suitable for split-mouth allocation.
- Clinical attachment loss consistent with Stage II or Stage III periodontitis.
- Ability and willingness to comply with the study protocol and attend all follow-up visits.
- Provision of written informed consent.
Exclusion Criteria:
- Current smokers or users of any tobacco products.
- Pregnant or lactating women.
- Patients with systemic diseases known to affect periodontal status or wound healing (e.g., uncontrolled diabetes mellitus, immunodeficiency disorders, osteoporosis requiring antiresorptive therapy).
- Use of systemic antibiotics, corticosteroids, immunosuppressive agents, or non-steroidal anti-inflammatory drugs within the previous 3 months.
- Periodontal therapy received within the previous 6 months.
- History of allergy or hypersensitivity to pomegranate or any component of the study materials.
- Orthodontic treatment during the study period.
- Participation in another clinical trial within the previous 6 months.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Pomegranate Peel Extract Gel
Periodontal sites receive scaling and root planing followed by subgingival application of pomegranate peel extract gel.
|
Locally delivered subgingival gel containing pomegranate peel extract administered after scaling and root planing.
|
|
Placebo-Komparator: Placebo Gel
Periodontal sites receive scaling and root planing followed by subgingival application of placebo gel with identical appearance and consistency.
|
Placebo gel without active ingredient, identical in appearance and consistency to the experimental gel, administered after scaling and root planing.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Probing Pocket Depth (PPD)
Zeitfenster: Baseline, 1 month, 3 months, and 6 months
|
Change in probing pocket depth (PPD), measured in millimeters using a calibrated periodontal probe at the selected periodontal sites.
|
Baseline, 1 month, 3 months, and 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Clinical Attachment Level (CAL)
Zeitfenster: Baseline, 1 month, 3 months, and 6 months
|
Change in clinical attachment level (CAL), measured in millimeters using a calibrated periodontal probe at the selected periodontal sites.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Plaque Index (PI)
Zeitfenster: Baseline, 1 month, 3 months, and 6 months
|
Change in plaque index (PI) assessed using the Silness and Löe Plaque Index.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Gingival Index (GI)
Zeitfenster: Baseline, 1 month, 3 months, and 6 months
|
Change in gingival index (GI) assessed using the Löe and Silness Gingival Index.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Bleeding on Probing (BOP)
Zeitfenster: Baseline, 1 month, 3 months, and 6 months
|
Change in bleeding on probing (BOP), assessed as the presence or absence of bleeding following gentle periodontal probing.
|
Baseline, 1 month, 3 months, and 6 months
|
|
Change in Gingival Crevicular Fluid Matrix Metalloproteinase-8 (MMP-8) Levels
Zeitfenster: Baseline, 1 month, 3 months, and 6 months
|
Change in gingival crevicular fluid matrix metalloproteinase-8 (MMP-8) concentration measured using enzyme-linked immunosorbent assay (ELISA).
|
Baseline, 1 month, 3 months, and 6 months
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Luchian I, Goriuc A, Sandu D, Covasa M. The Role of Matrix Metalloproteinases (MMP-8, MMP-9, MMP-13) in Periodontal and Peri-Implant Pathological Processes. Int J Mol Sci. 2022 Feb 4;23(3):1806. doi: 10.3390/ijms23031806.
- Tyagi P, Dodwad V, Kukreja BJ, Kukreja P. A comparison of the efficacy of scaling and root planning with application of pomegranate chip, pomegranate gel, and scaling and root planing in sufferers with adult periodontitis - A prospective study. J Indian Soc Periodontol. 2021 Jan-Feb;25(1):41-46. doi: 10.4103/jisp.jisp_243_20. Epub 2021 Jan 7.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- P-PD-26-09
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .